Nuveen
PACB icon

Nuveen’s Pacific Biosciences PACB Stock Holding History

Nuveen’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-185,600
Closed -$6K – 3444
2021
Q2 		$6K Buy
+185,600
New +$5.4M ﹤0.01% 3300
2021
Q1 		– Sell
-102,200
Closed -$3K – 3399
2020
Q4 		$3K Buy
+102,200
New +$1.74M ﹤0.01% 3294

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Nuveen's PACB Position: Q2 2026 in Review

Nuveen reduced its Pacific Biosciences (PACB) stake by 65% in Q2 2026, selling an estimated $2.8M and leaving 1,023,113 shares worth $1.72M. The position accounts for ﹤0.01% of the portfolio, ranked #2651.

Nuveen first reported a position in PACB in Q2 2019 and has held it in 29 quarters since. The position peaked at $44.7M in Q2 2021. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Nuveen held 1,023,113 shares of Pacific Biosciences worth $1.72M as of Q2 2026.
  • Nuveen sold 1,927,816 Pacific Biosciences shares in Q2 2026, an estimated $2.8M.
  • Pacific Biosciences made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2651 holding.
  • Nuveen first reported a position in Pacific Biosciences in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Pacific Biosciences position peaked at $44.7M in Q2 2021.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.